Company Overview
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
Why Investors Should Care
Revenue has grown at a 42.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $176.03M (+39.9% YoY); net profit $-116.79M.
- Trailing 12 Months Year-on-year growth — revenue +41.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.10% |
| 1 Year: | 41.30% |
Stock Price Performance
| 1 Year: | -9.14% |
| 6 Months: | -14.28% |
| 3 Months: | -6.20% |
| 1 Month: | -18.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 42.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HTFL Heartflow, Inc. R2K | 27.25 | -8.82 | $2.35B | 0.00% | -20.20% | -135.31% | 42.10% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 31.05M | 32.93M | 37.20M | 43.42M | 46.28M | 52.59M |
| Gross Profit | - | 23.84M | 24.94M | 27.94M | 32.78M | 35.41M | 42.16M |
| Operating Income | - | -14.18M | -14.93M | -17.50M | -13.71M | -15.10M | -29.50M |
| Net Income | -20.93M | -23.38M | -19.14M | -32.34M | -9.20M | -50.85M | -27.38M |
| Diluted EPS | - | -4.66 | -3.43 | -5.25 | -1.46 | -1.04 | -0.32 |
| R&D Expense | - | 9.93M | 11.86M | 13.92M | 15.03M | 17.30M | 21.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 87.17M | 125.81M | 176.03M |
| Gross Profit | 58.05M | 94.45M | 135.20M |
| Operating Income | -72.91M | -61.22M | -64.07M |
| Net Income | -95.66M | -96.43M | -116.79M |
| Diluted EPS | -25.32 | -17.98 | -3.17 |
| R&D Expense | 35.85M | 43.52M | 64.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 118.70M | 359.45M |
| Total Equity | -693.64M | -777.56M | -859.48M | 300.65M |
| Cash & Equivalents | - | 122.77M | 51.37M | 44.78M |
| Total Liabilities | - | - | 209.62M | 58.80M |
| Current Liabilities | - | - | 33.60M | 42.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -76.43M | -69.00M | -54.02M |
| Investing Cash Flow | -6.11M | -4.36M | -238.57M |
| Financing Cash Flow | 169.32M | 2.24M | 286.04M |
| Capital Expenditure | -6.11M | -4.36M | -5.03M |
| Free Cash Flow | -82.54M | -73.36M | -59.05M |
| Share Buybacks | 228.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 66.6% | 75.1% | 76.8% |
| Operating Margin % | -83.6% | -48.7% | -36.4% |
| Net Margin % | -109.7% | -76.6% | -66.3% |
| ROE % | 12.3% | 11.2% | -38.8% |
| ROCE % | - | -71.9% | -20.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wellington Management Group, LLP | 13.89% | 11.98M | $323.82M |
| 2 | Bain Capital Life Sciences Investors, LLC | 12.12% | 10.45M | $282.36M |
| 3 | FMR, LLC | 6.26% | 5.40M | $145.88M |
| 4 | BAMCO Inc. | 4.44% | 3.83M | $103.44M |
| 5 | Janus Henderson Group PLC | 2.53% | 2.18M | $58.94M |
| 6 | HealthCor Partners Management LP | 2.41% | 2.08M | $56.27M |
| 7 | Vanguard Portfolio Management LLC | 2.37% | 2.05M | $55.29M |
| 8 | Invesco Ltd. | 2.22% | 1.91M | $51.70M |
| 9 | Vanguard Capital Management LLC | 2.20% | 1.89M | $51.17M |
| 10 | Blackrock Inc. | 1.70% | 1.46M | $39.53M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HTFL
Campbell D. Rogers plans 9,219-share HTFL stock sale on NASDAQ - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOelFmVFdta3lCTllHYllBeGszOWY5UGNsZVBGOWNGaGpIS1lKRzZlZGJKN3JscGVMUlV0RXlMQjB1WVBvY1N3N3A2MjljY2pZMHluTUkxTnNwRXdhLVVwVGd2RFdkeUsxbm5vLTRNOHdIdVlsaU5SNEhXWWhER1hEZVFjbGYzckRfUWhMd0…
Stifel reiterates HeartFlow stock rating after cardiology meeting By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQR2l5eUpWeVItWG5VQ2VQMl9ib1kxQ3pTNjhpSkcyWUY2WGtzQVhEaG4ydFRHS1huTzdydGVVakdibDFhZVlSVE9HbUhwZTJDdzEwMmdQVi1xRWVtZzR5SktXOFc5cXd3Y19yVWxKUXJLVEk0UE9oODgycGZvbUMzXzFrcTI5SUkwbHVOM3…
HeartFlow: A Premium AI Diagnostics Story (NASDAQ:HTFL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPa0FrSjFFYTVzQjhGaDRxV2hTZUMySW5pVEZWV0MtT3hKOWpvOWNIY1AtTHB0V093S1FqMUhJVDFINDB5WlN2UjAxYXVCQ0ZiN3JOMnZKYUtjeXFDQVdwRHlhLWY4SUdpSGRSWUdUMWtkTndxV3RMQ3JwVzRrWUplcUtaNEE5YlF5aWlpZV…
HeartFlow Sees Insider Stock Selling - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUmVYVHVxckYwMjlfZUNkeDI4a2F4anVJQTVBQW1PRGdvT1Fnc0kxdFpzN3hNMkYtcnFfMlNfc3RFaU1hSmZveHFTYllXTVZwdFJldXZEQXpnWGpYZGdHdlpNZXpSUTlaTTIxaGxBVTJxU3VUaGF2UGZSTEJHLXBONXVIeWFlaUgxX3U5d1…
HeartFlow Inc (HTFL) CEO John Farquhar Sells 22,562 Shares - GuruFocus
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNcVhTWTRKc2J4SzJ3TkYtR1Y3d05KaHdoSnA4aTlkQ29LNjRISUozbE1DQ3hFejVWdy1iWkZlakp0ZHZ6QURjR2M4MEFWTG03YXBvQVBrZWpNZkJkZTQ2cHg0Y3lsaXZ5al94NUdiMDN5SkN2Mnh2cFFHcmNPVDJyNkx4NVhkeEpDRThMX0…
Heartflow Inc. (HTFL) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQM3JibGJGSnY0cXI4aEliRUVzcE9BY1RZYnA0QkZNMC1DWmxjLVFXdVdxTGUyM2hLN3ZaUVJla3ItUVNsRUNIV3dHVzJMcVpKUmFWOVhVaFVvZ1NYalZ5SS1DbkJpakpOa0xjcXpfZGlLd1JROVJLc1EyLTZmMWV1OUowYThLdnBSeE9Zd0…
HTFL — Frequently Asked Questions
What is the current share price of Heartflow, Inc. (HTFL)?
As of 2026-07-15 16:51 PDT, Heartflow, Inc. (HTFL) trades at $27.25 on NasdaqGS. Its 52-week range is $20.49 to $39.91.
What is the market capitalisation of HTFL?
Heartflow, Inc. (HTFL) has a market capitalisation of $2.35B on NasdaqGS.
What is the P/E ratio of HTFL?
HTFL trades at a trailing price-to-earnings (P/E) ratio of -8.82. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 8.14.
What is the return on equity (ROE) of HTFL?
HTFL has a return on equity (ROE) of -135.31%. Its return on capital employed (ROCE) is -20.20%.
Is HTFL a good stock to buy?
This page provides a data-driven analysis of Heartflow, Inc. (HTFL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.